You are here: Industry Insights > Blockbuster

News List

AstraZeneca, Merck's Lynparza scores speedy review in blockbuster ovarian cancer market fiercepharma
November 13, 2018
Last month, AstraZeneca and Merck’s Lynparza posted big-time ovarian cancer data, and regulators are taking note.
GlaxoSmithKline's Shingrix zooms toward blockbuster status despite tight supply fiercepharma
November 01, 2018
GlaxoSmithKline's Shingrix zooms toward blockbuster status despite tight supply
Shire eyes blockbuster sales with 'best-in-class' HAE drug Takhzyro fiercepharma
August 27, 2018
Jefferies analyst David Steinberg predicts Shire's Takhzyro could hit $1.8 billion in peak sales.
With latest data, has Roche's Tecentriq found a blockbuster lung cancer niche? fiercepharma
June 26, 2018
So far, Roche’s Tecentriq hasn’t been able to find a piece of the lung cancer market to call its own. But that may change after its latest trial win.
Current Situation of Biosimilars in China III: Analysis of Biosimilars of Five Blockbust Tang
December 27, 2017
The biosimilars in China just started, and the biosimilar review and approval policies continue to be improved.
Overview of NDA of FDA in Q3: Nearly Half of the 11 New Drugs Possessing “Blockbuster” Potential en-cphi.cn
October 13, 2017
FDA approved 11 new drugs in total (see the attached table for the details) in 2017 Q3. Time is the most objective judge and good things will always stand its tests.

Previous page 1 2 Next page